Seeking a come-from-behind win, Eli Lilly lands big approval for next-gen diabetes drug
Eli Lilly has clinched a key OK for tirzepatide, drawing the curtain on what it hopes will be a major cardiometabolic franchise and a serious rival to a megablockbuster from Novo Nordisk.
With the FDA approval, Lilly will start marketing tirzepatide injection as Mounjaro to adults with Type 2 diabetes, the first such treatment that’s also a dual GIP/GLP-1 receptor agonist.
But the label also comes with a black box warning regarding thyroid C-cell tumors, and the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.